To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer

Clinical trial NCT05365178 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05365178
Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

HR-positive, HER2-negative Breast Neoplasms

Start date: 2022-07-01
Primary completion: 2025-07-02
Enrollment: 432

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.